During the past decade, there has been a dramatic shift in the prioritization of dry eye disease (DED) by both physicians and industry. Once relegated to the lowest position among routine assessments, ocular surface disease (OSD) is now recognized as a chronic and progressive disease state. Ten years ago, doctors used the limited diagnostic options that were available, and little about the complex origins of DED was truly understood. Attention to this mercurial condition has increased thanks to several developments, including an evolution of diagnostic technologies, greater awareness of the potential refractive impact of DED, and a growing patient population.

THE DIAGNOSTIC PROCESS

Diagnostics are the key to accurately identifying the root cause or causes of a patient’s OSD. Without these tools, doctors tend to take a troubleshooting approach to treatment in which they try one option after another. Each failure disheartens both doctor and patient. Many DED patients have seen numerous doctors without success and are searching for someone to truly partner with them.

The first and most essential part of any ocular surface evaluation is the medical history. Careful acquisition of a detailed history not only directs the examination but also builds rapport with the patient. A comprehensive history allows the patient to identify therapeutic successes and failures and to recognize environmental triggers that may exacerbate the condition.

After the history, a complete DED evaluation often includes tear osmolarity, meibography, tear breakup time, aqueous volume, and other tests.

Elevated levels of matrix metalloproteinase 9 (MMP-9) are consistently found in patients with DED. The InflammaDry (Rapid Pathogen Screening) is useful for identifying the presence of this marker in a tear sample taken from the palpebral conjunctiva (Figure 1). Within 10 minutes, the test provides results with 85% sensitivity and 94% specificity (data on file with Rapid Pathogen Screening).

In my experience, InflammaDry is a particularly beneficial tool for diagnosing patients who report significant symptoms but who do not show corresponding clinical signs. A positive test identifies the presence of MMP-9, but it does not point to the specific origin. In our clinic, my colleagues and I initially used an Ocular Surface Disease Index (OSDI) score of 50 or greater to trigger the order for InflammaDry. Recent evidence suggests that MMP-9 does not necessarily correlate with symptoms, however, so criteria will be broadening for use of the test.

DIRECTING TREATMENT

No flowchart can comprehensively direct the treatment of DED because of its multifactorial nature, but diagnostic testing can help to organize and narrow the differential diagnoses. Meibography, tear prism height, and aqueous volume measurements aid in determining if the patient has an aqueous-deficient, evaporative, or mixed form of OSD. This basic distinction can allow the doctor to initiate therapeutically effective treatments.

When tear insufficiency is suspected, punctal plugs can be a useful approach to therapy in select patients. If blepharitis or meibomian gland dysfunction is detected or suspected, treatment often begins with addressing any physical...
DED EXPERTS PICK TOP DEVICES AND DISCUSS THE FUTURE

By Whitney Hauser, OD; Leslie E. O’Dell, OD; Richard B. Mangan, OD; and Scott G. Hauswirth, OD

In recent years, there has been significant progress made in the field of ocular surface disease (OSD), both from a diagnostic and therapeutic standpoint. For those interested in taking dry eye disease (DED) management to the next level, it can be a daunting task to determine which technology, test, or treatment modality should be incorporated into your practice first. Given this, we asked some experts in the field of DED a few questions that may provide some insight.

—Executive Editor Conni Bergmann Koury

Question: If you could select only three devices (be it diagnostic, therapeutic, or a mix of both), what would be at the top of your list for your DED practice and why?

WHITNEY HAUSER, OD

The top three items for my DED practice are lissamine green, meibography, and the BlephEx device (BlephEx).

Lissamine green. This dye is essential for the early diagnosis of mild to moderate cases of DED and should be a fundamental for all eye care providers’ practices. It not only stains dead or devitalized cells on the cornea and conjunctiva, but lissamine green also highlights the Line of Marx and identifies the progression of meibomian gland dysfunction (MGD).

Meibography. Considering that over 80% of DED is evaporative in nature, meibography is critical to making the proper diagnosis. I find meibography useful for educating patients about their condition and setting appropriate expectations for those with atrophy and truncation. Both Oculus and TearScience offer tools that include meibography and other valuable features to diagnose and monitor the progression of DED.

BlephEx. From a treatment perspective, I like the utility of BlephEx. I find the device exceptionally effective for treating both MGD and anterior blepharitis. I have seen an improvement in patients’ symptoms and tear breakup time as well as enhanced meibomian gland function. Because Demodex occurs in 84% of patients over the age of 60 years, there is no shortage of people who can benefit. The price of the unit and disposables is not prohibitive for doctors or patients.

RICHARD B. MANGAN, OD

My top three DED technologies are slit-lamp photography, meibography, and the use of compounded products.

Slit-lamp photography. Whether a patient has mixed blepharitis, Demodex mites, lissamine green staining, or an incomplete blink reflex, slit-lamp photography with video capability can make a dramatic statement in the eyes of your patient (no pun intended). Not only is it a powerful teaching tool, but it is also an accountability tool. When I show patients with mixed blepharitis what their eyelids look like and then tell them that I will be taking pictures again in 4 to 6 weeks to compare, they are more likely to stick with the prescribed regimen.

Meibography. Drs. Hauser and O’Dell did a great job of stressing the importance of this technology. I would add that patients respond to the images I show them either at the screen or as a printout. Visual aids help support patients’ buy-in and, in my opinion, improve compliance.

Compounded products. My dry eye clinic showed exponential growth after I started offering compounded or formulated products. I knew I was on the right track when one patient made it routine to drive several hours to my practice for autologous serum every 3 to 4 months. A delightful lady with Sjögren syndrome, who had been on maximum medical therapy prior to starting...
autologous serum, said for the first time she could finally leave the house without having significant eye discomfort. I even had a pilot who wanted to fly in from Chattanooga, Tennessee, for the treatment. This was before I was able to find him a more local alternative.

There are a number of good commercial products on the market now for OSD, but a number of patients remain sensitive to preservatives found in these commercial products or may need an off-label alternative that better reflects the severity of their condition.

**Bonus pick.** I think many clinicians focus on adding or initiating the treatment of OSD instead of looking at ways to prevent the condition or improve the ocular surface by eliminating current treatments for concomitant disease. One example of technology that can do this is selective laser trabeculoplasty. Studies show that even a prostaglandin analogue at bedtime can increase surface inflammation and exacerbate OSD symptoms. Selective laser trabeculoplasty utilized earlier in the management of open-angle glaucoma may bridge the gap in preserving the ocular surface until a microinvasive glaucoma surgery procedure can be introduced during routine cataract surgery.

**SCOTT G. HAUSWIRTH, OD**

My top choices are anterior segment photography, a PRK spatula, and compounding pharmacies.

**Anterior segment photography (including meibography).** I take a large number of ocular surface photographs such as images of staining, lid margin changes, blepharitis, anterior basement membrane dystrophy, etc., to use as patient education tools, in addition to documenting baseline and progression markers. I am convinced there is no more powerful tool than using a patient’s own eye for education on what is “normal” versus explaining an anatomical change or a demonstration of disease state. In my mind, images take a little bit of the mystery of disease away from the patient’s perspective and make it tangible. I do not even think it is necessary to have the most expensive technology; if the clinician has a transilluminator, he or she can take a reasonable photograph of truncation or gland dropout, and today’s smartphones can easily capture these images.

**PRK spatula.** The Lindstrom/Vorkas Excimer Spatula (Beaver-Visitec International) is a simple yet incredibly diverse piece of equipment that I use several times a day. From lid margin debridement and debulking of cylindrical dandruff in blepharitis treatments to cleaning up the edges of a corneal erosion or debridement, this tool can handle a variety of situations. The expense to the practitioner is minimal, and there are no ongoing costs. This is a simple device that I do not think I could do without.

**Compounded products.** I am in agreement with Dr. Mangan on my third selection. When it comes to taking a DED practice to the next level, establishing a relationship with a good compounding pharmacy is essential. The one I use has been able to compound varying concentrations of nonpreserved sodium hyaluronate with or without steroid added, autologous serum, and other products that are more specialized for patients with advanced disease.

**WHITNEY HAUSER, OD**

We eye care providers have witnessed a tidal wave of diagnostic testing for OSD in the past several years, and each metric adds a new piece to the DED puzzle. Recent research has highlighted biometric changes in cataract surgery patients with OSD and a demographic shift toward younger patients’ having disease, likely due in large part to their use of digital devices. Because of the complex and multifactorial nature of DED, there are countless factors to weigh.

One topic almost entirely neglected clinically and from a research perspective, however, is the role of cosmetics use in DED. Cosmetics applied around the eyes and products used to remove them may contribute to MGD or inflammation in some patients. As doctors, we routinely review medications, nutrition, and hormonal changes with our patients but fail to call attention to a lid margin laden with make-up or to ask about products used. One of the next frontiers of DED is exploring how cosmetics may contribute to both the short- and long-term course of the condition. I would like to see the lines of communication between doctor and patient be more open.

**LESLIE E. O’DELL, OD**

Thanks to the efforts of the Tear Film and Ocular Surface Society, we now have an evidence-based approach to the diagnosis and management of DED with the Dry Eye Workshop report and the MGD workshop. In the future, I would like to see a shift from a reactive approach to a preventive approach to DED treatment and the adoption of the dental model.

With the impact of digital devices on the ocular surface combined with external stressors like cosmetics and the environment, our focus should turn to younger patients. We need to educate them on the risks associated with their digital devices, screen them aggressively for early signs of disease, and initiate their treatment before symptoms begin. We should be evaluating lid health and recommending this examination be repeated every 6 months to debride the lid margin and maintain meibomian gland function. We must educate patients on the importance of the ingredients in the products they use around their eyes and on their faces. We should take it one step further and provide patients with information on how to safely wear and remove their cosmetics to protect the ocular surface.

**RICHARD B. MANGAN, OD**

I think Dr. O’Dell really hits the mark in her comments about being proactive instead of reactive. One example is surface optimization before cataract or refractive surgery. We are now in the baby boomer era (they account for one-third of all refractive procedures), and these patients are tech savvy and expect superior outcomes. Considering that the number one cause of refractive errors is a need for better vision, many patients have asked if they can change from one chair to another to another,” or “can I have a better vision correction.” We can now offer them the option of dry eye surgery with a prostaglandin analogue at bedtime can increase surface inflammation and exacerbate OSD symptoms.

One option that I would like to see more of is the adoption of the dental model. In the future, I would like to see a shift toward younger patients’ having disease, likely due in large part to their use of digital devices. Because of the complex and multifactorial nature of DED, there are countless factors to weigh.

One topic almost entirely neglected clinically and from a research perspective, however, is the role of cosmetics use in DED. Cosmetics applied around the eyes and products used to remove them may contribute to MGD or inflammation in some patients. As doctors, we routinely review medications, nutrition, and hormonal changes with our patients but fail to call attention to a lid margin laden with make-up or to ask about products used. One of the next frontiers of DED is exploring how cosmetics may contribute to both the short- and long-term course of the condition. I would like to see the lines of communication between doctor and patient be more open.

**CATA RACT & REFRACTIVE SURGERY TODAY**

Question: There have certainly been significant technological advances in the field of DED during the past decade. Given this, what do you think eye care providers and researchers should focus on as we move forward? Also, what would you like to see change or improve about how we approach OSD?

**WHITNEY HAUSER, OD**

We eye care providers have witnessed a tidal wave of diagnostic testing for OSD in the past several years, and each metric adds a new piece to the DED puzzle. Recent research has highlighted biometric changes in cataract surgery patients with OSD and a demographic shift toward younger patients’ having disease, likely due in large part to their use of digital devices. Because of the complex and multifactorial nature of DED, there are countless factors to weigh.

One topic almost entirely neglected clinically and from a research perspective, however, is the role of cosmetics use in DED. Cosmetics applied around the eyes and products used to remove them may contribute to MGD or inflammation in some patients. As doctors, we routinely review medications, nutrition, and hormonal changes with our patients but fail to call attention to a lid margin laden with make-up or to ask about products used. One of the next frontiers of DED is exploring how cosmetics may contribute to both the short- and long-term course of the condition. I would like to see the lines of communication between doctor and patient be more open.

**LESLIE E. O’DELL, OD**

Thanks to the efforts of the Tear Film and Ocular Surface Society, we now have an evidence-based approach to the diagnosis and management of DED with the Dry Eye Workshop report and the MGD workshop. In the future, I would like to see a shift from a reactive approach to a preventive approach to DED treatment and the adoption of the dental model.

With the impact of digital devices on the ocular surface combined with external stressors like cosmetics and the environment, our focus should turn to younger patients. We need to educate them on the risks associated with their digital devices, screen them aggressively for early signs of disease, and initiate their treatment before symptoms begin. We should be evaluating lid health and recommending this examination be repeated every 6 months to debride the lid margin and maintain meibomian gland function. We must educate patients on the importance of the ingredients in the products they use around their eyes and on their faces. We should take it one step further and provide patients with information on how to safely wear and remove their cosmetics to protect the ocular surface.

**RICHARD B. MANGAN, OD**

I think Dr. O’Dell really hits the mark in her comments about being proactive instead of reactive. One example is surface optimization before cataract or refractive surgery. We are now in the baby boomer era (they account for one-third of all refractive procedures), and these patients are tech savvy and expect superior outcomes. Considering that the number one cause of refractive errors is a need for better vision, many patients have asked if they can change from one chair to another to another.” or “can I have a better vision correction.” We can now offer them the option of dry eye surgery with a prostaglandin analogue at bedtime can increase surface inflammation and exacerbate OSD symptoms.

One option that I would like to see more of is the adoption of the dental model. In the future, I would like to see a shift toward younger patients’ having disease, likely due in large part to their use of digital devices. Because of the complex and multifactorial nature of DED, there are countless factors to weigh.

One topic almost entirely neglected clinically and from a research perspective, however, is the role of cosmetics use in DED. Cosmetics applied around the eyes and products used to remove them may contribute to MGD or inflammation in some patients. As doctors, we routinely review medications, nutrition, and hormonal changes with our patients but fail to call attention to a lid margin laden with make-up or to ask about products used. One of the next frontiers of DED is exploring how cosmetics may contribute to both the short- and long-term course of the condition. I would like to see the lines of communication between doctor and patient be more open.
surprise after cataract surgery is an error in measurement of the cornea (precorneal tear film) and that the top reason for postoperative visual complaints is related to OSD, primary eye care providers need to play a larger role in surface optimization before referring patients for surgery. Although the latest negatively aspheric IOL designs provide superior optics compared to standard implants, they are less forgiving when it comes to residual refractive error, decentration, and tilt.

Proactively educating patients on premium lenses offers an opportunity for eye care providers to design an ocular surface treatment plan that will provide the greatest odds for a 20/happy patient postoperatively. A happy patient tells three friends, but an unhappy one tells 10.

SCOTT G. HAUSWIRTH, OD

I must comment that, although the diagnostic technology that has been developed commercially for clinical use has been a fantastic and helpful addition to our practices, there are still a number of limitations with the current iteration. I expect that this will lead to revisions and further evolution of the technology to make the tools more reliable and accurate when it comes to diagnosis and more effective at being able to hone an effective management strategy. After all, this is only the first generation of diagnostic technology.

I also believe that we as eye care providers need to move toward a better understanding of the ocular surface unit as a whole. What we now think of as simply “dry eye disease” is really a complex and dynamic interaction of tissue mechanics, fluids, glands, and neuronal communication issues, and I think we must become more fluent in understanding and teasing these individual dysfunctions apart.

I absolutely agree that, from a patient management standpoint, the best approach is a proactive one, enabling us to engage with patients at an earlier stage of the disease.

Additional considerations such as active infection or sensitivity to the material may exclude patients from the insertion of either type of plug.

The main advantage of an absorbable plug is that it is, by definition, not a permanent choice for the doctor or patient. The capricious nature of DED requires physicians to change their therapeutic recommendations over time. Remedies that work for months may not become part of a long-term regimen.

The Comfortear Lacrisolve 180 Absorbable Punctum Plug (Paragon BioTeck) is one way to achieve lasting, effective occlusion without a permanent commitment. Most temporary plugs dissolve or migrate in 90 days, but this product maintains its position for approximately 180 days. If the patient finds relief from these temporary plugs, then he or she may benefit from a semipermanent silicone plug.

IPL THERAPY

When conventional meibomitis treatments such as warm compresses and topical medications fail to bring relief, more
advanced care becomes necessary. The efficacy of IPL therapy for the treatment of DED was serendipitously discovered in 2002 by Rolando Toyos, MD.1 IPL was originally recommended to diminish redness in patients with the dermatological signs of erythematotelangiectatic rosacea, but he found that patients with DED reported that the treatments decreased their symptoms as well.

Although the treatment’s mechanism of action is not well understood and warrants further study, preliminary results have been promising.2 The key advantages of the thermal effects of the xenon flashlamp are suspected to be objective improvements in meibomian gland secretions and tear break-up time, subjective improvement in the patient’s comfort, a decrease in the bacterial load at the eyelid margin, diminished lid telangiectasia, and an aesthetic improvement in the skin.

My colleagues and I use the M22 (Lumenis) in our practice to perform IPL. Many of my patients who experience success with IPL treatment have the evaporative form of DED, but I have also observed favorable outcomes in patients with aqueous-deficient DED associated with Sjögren syndrome. Certainly, patients diagnosed with rosacea who are experiencing DED symptoms are likely to be good candidates for IPL.

Specific inclusion and exclusion criteria must be strictly followed to ensure that patients achieve maximum benefit with minimum risk. A survey of skin type must be completed to determine the patient’s Fitzpatrick skin type. Skin types I, II, III, and IV are eligible with appropriate use of the filters available with the M22, provided there are no other contraindications. A test spot is recommended on the malar region where the skin is similar to the treatment area. A normal skin reaction will result in a slight pink/red flush that quickly fades. Patients must not take photosensitive medications such as doxycycline during the treatment course.

**CASE STUDY**
A 41-year-old Asian woman presented with a lengthy history of dry eyes. She had been placed on a regimen of cyclosporine ophthalmic emulsion 0.05% (Restasis; Allergan) twice daily several years ago, but she discontinued treatment after 1 month because she thought the drops were ineffective. The eye care provider she had visited most recently gave her lid hygiene products and artificial tears, but their use had not lessened the patient’s symptoms.

A thorough evaluation suggested aqueous deficiency. As part of the diagnostic battery, the patient underwent an InflammaDry test, and a positive result was recorded.

The patient was educated about the role of inflammation in her OSD. Loteprednol etabonate ophthalmic suspension 0.5% (Lotemax; Bausch + Lomb) twice daily and cyclosporine twice daily were prescribed.

One month later, not only had the patient’s OSDI score improved, but she also had a negative InflammaDry test result. The latter made an impact on her long-term prescribed medical therapy, which had previously been a barrier to success.

**CONCLUSION**
As new tools and technologies empower clinicians, it is fast becoming clear that OSD management simply is not one size fits all. Effective treatment requires a thorough, analytical understanding of the issue at hand; applying a broad treatment to every patient takes little time but ultimately benefits no one. A rigorous approach to diagnosis, using methods new and proven, ensures every patient receives the best care possible instead of the most expedient.


**Whitney Hauser, OD**
- assistant professor at Southern College of Optometry, Memphis, Tennessee
- (901) 229-2137; whitneyhauser@sco.edu
- financial disclosure: board member for Paragon BioTeck and TearLab; speaker for and/or consultant to Akorn, Allergan, BioTissue, Lumenis, NovaBay, Science Based Health, Shire, TearScience

Figure 2. Within 10 minutes, the test provides results with 85% sensitivity and 94% specificity.